15.88
price down icon6.20%   -1.05
after-market After Hours: 15.88
loading
Novocure Ltd stock is traded at $15.88, with a volume of 1.96M. It is down -6.20% in the last 24 hours and up +50.52% over the past month. NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
See More
Previous Close:
$16.93
Open:
$16.75
24h Volume:
1.96M
Relative Volume:
1.00
Market Cap:
$1.84B
Revenue:
$674.41M
Net Income/Loss:
$-173.05M
P/E Ratio:
-10.35
EPS:
-1.5343
Net Cash Flow:
$-48.07M
1W Performance:
+31.02%
1M Performance:
+50.52%
6M Performance:
+36.78%
1Y Performance:
-10.59%
1-Day Range:
Value
$15.79
$16.76
1-Week Range:
Value
$11.61
$17.22
52-Week Range:
Value
$9.82
$20.06

Novocure Ltd Stock (NVCR) Company Profile

Name
Name
Novocure Ltd
Name
Phone
44 (0)15 3475 6700
Name
Address
NO. 4 THE FORUM, ST. HELIER
Name
Employee
1,605
Name
Twitter
@novocure
Name
Next Earnings Date
2026-04-30
Name
Latest SEC Filings
Name
NVCR's Discussions on Twitter

Compare NVCR vs ABT, SYK, MDT, BSX, EW

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
NVCR icon
NVCR
Novocure Ltd
15.88 1.96B 674.41M -173.05M -48.07M -1.5343
ABT icon
ABT
Abbott Laboratories
87.17 152.48B 45.13B 6.28B 7.38B 3.5895
SYK icon
SYK
Stryker Corp
295.25 111.40B 25.27B 3.34B 4.57B 8.6358
MDT icon
MDT
Medtronic Plc
77.79 100.53B 35.48B 4.64B 5.41B 3.582
BSX icon
BSX
Boston Scientific Corp
55.98 84.50B 20.62B 3.56B 3.48B 2.3847
EW icon
EW
Edwards Lifesciences Corp
82.91 48.04B 6.30B 1.07B 1.34B 1.8406

Novocure Ltd Stock (NVCR) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-25-25 Downgrade Wells Fargo Overweight → Equal Weight
Jul-08-25 Initiated Ladenburg Thalmann Buy
Dec-02-24 Upgrade Evercore ISI In-line → Outperform
Oct-16-24 Upgrade H.C. Wainwright Neutral → Buy
Nov-20-23 Resumed JP Morgan Neutral
Aug-28-23 Downgrade H.C. Wainwright Buy → Neutral
Aug-08-23 Upgrade Piper Sandler Neutral → Overweight
Aug-04-23 Initiated SVB Securities Outperform
Jul-31-23 Upgrade Evercore ISI Underperform → In-line
Jun-07-23 Upgrade Wedbush Underperform → Neutral
May-16-23 Upgrade Wells Fargo Equal Weight → Overweight
Mar-17-23 Downgrade JP Morgan Neutral → Underweight
Jan-06-23 Downgrade Wells Fargo Overweight → Equal Weight
Jan-05-23 Reiterated H.C. Wainwright Buy
Nov-29-22 Upgrade Wells Fargo Equal Weight → Overweight
Oct-24-22 Downgrade Piper Sandler Overweight → Neutral
Jul-05-22 Downgrade Evercore ISI In-line → Underperform
May-16-22 Initiated H.C. Wainwright Buy
Feb-08-22 Initiated Loop Capital Buy
Feb-02-22 Upgrade Oppenheimer Perform → Outperform
Jan-20-22 Upgrade Truist Hold → Buy
Jan-03-22 Upgrade Evercore ISI Underperform → In-line
Jul-01-21 Downgrade Mizuho Buy → Neutral
Apr-14-21 Downgrade Wedbush Neutral → Underperform
Jan-25-21 Reiterated Piper Sandler Overweight
Sep-23-20 Initiated Northland Capital Outperform
Sep-18-20 Downgrade Wells Fargo Overweight → Equal Weight
Sep-17-20 Downgrade Truist Buy → Hold
Jun-01-20 Resumed Oppenheimer Perform
May-01-20 Downgrade Oppenheimer Outperform → Perform
Apr-09-20 Downgrade Evercore ISI In-line → Underperform
Mar-05-20 Upgrade Wells Fargo Equal Weight → Overweight
Jan-02-20 Downgrade Evercore ISI Outperform → In-line
Jul-29-19 Upgrade SunTrust Hold → Buy
Jul-26-19 Downgrade JP Morgan Overweight → Neutral
Jul-26-19 Downgrade Wedbush Outperform → Neutral
Mar-20-19 Initiated SunTrust Hold
Nov-02-18 Downgrade Wells Fargo Outperform → Market Perform
Jul-16-18 Initiated Evercore ISI Outperform
Apr-18-18 Reiterated Mizuho Buy
Feb-23-18 Reiterated Mizuho Buy
May-24-17 Upgrade Wells Fargo Market Perform → Outperform
Jul-29-16 Reiterated Wedbush Outperform
Jan-19-16 Initiated Barclays Underweight
Dec-02-15 Initiated Deutsche Bank Hold
View All

Novocure Ltd Stock (NVCR) Latest News

pulisher
12:06 PM

Why NovoCure (NVCR) Is Up 33.2% After FDA Clears Optune Pax And Guidance Ticks Higher - Sahm

12:06 PM
pulisher
May 04, 2026

Wells Fargo Maintains Novocure(NVCR.US) With Hold Rating, Raises Target Price to $17 - Moomoo

May 04, 2026
pulisher
May 03, 2026

NovoCure’s Optune Pax Win And TRIDENT Data Shape Growth Outlook - Sahm

May 03, 2026
pulisher
May 02, 2026

NovoCure Limited Surges As Guidance Hike Fuels NVCR Rally - timothysykes.com

May 02, 2026
pulisher
May 02, 2026

Here's What Analysts Are Forecasting For NovoCure Limited (NASDAQ:NVCR) After Its First-Quarter Results - Moomoo

May 02, 2026
pulisher
May 02, 2026

NovoCure Limited (NASDAQ:NVCR) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? - Yahoo Finance

May 02, 2026
pulisher
May 01, 2026

NovoCure Reports Q1 2026 Results: Full Earnings Call Transcript - Sahm

May 01, 2026
pulisher
May 01, 2026

NovoCure Ltd (NVCR) Shares Surge 9.3% -- What GF Score of 70 Tel - GuruFocus

May 01, 2026
pulisher
May 01, 2026

NovoCure (NASDAQ:NVCR) Trading 6.8% HigherShould You Buy? - MarketBeat

May 01, 2026
pulisher
May 01, 2026

NVCR Maintained by Evercore ISI Group -- Price Target Raised to $20 - GuruFocus

May 01, 2026
pulisher
May 01, 2026

Evercore Maintains Novocure(NVCR.US) With Buy Rating, Raises Target Price to $20 - Moomoo

May 01, 2026
pulisher
May 01, 2026

NovoCure Ltd (NVCR) Q1 2026 Earnings Call Highlights: Revenue Gr - GuruFocus

May 01, 2026
pulisher
May 01, 2026

symbol__ Stock Quote Price and Forecast - CNN

May 01, 2026
pulisher
May 01, 2026

NovoCure (NVCR) Earnings Story Centers On 20.6% Revenue Growth Versus Ongoing Losses - simplywall.st

May 01, 2026
pulisher
Apr 30, 2026

MSN Money - MSN

Apr 30, 2026
pulisher
Apr 30, 2026

NovoCure Earnings Call Highlights Growth, One-Time Hit - TipRanks

Apr 30, 2026
pulisher
Apr 30, 2026

NovoCure Limited Q1 2026 Earnings Call Summary - Yahoo Finance

Apr 30, 2026
pulisher
Apr 30, 2026

NovoCure (NASDAQ:NVCR) Announces Earnings Results - MarketBeat

Apr 30, 2026
pulisher
Apr 30, 2026

NovoCure Ltd Q1 2026 Financial Results: Revenues, Losses, and Key Forward-Looking Statements - Minichart

Apr 30, 2026
pulisher
Apr 30, 2026

H.C. Wainwright Maintains Novocure(NVCR.US) With Buy Rating, Cuts Target Price to $48 - Moomoo

Apr 30, 2026
pulisher
Apr 30, 2026

NovoCure (NVCR) Q1 2026 Earnings Transcript - The Globe and Mail

Apr 30, 2026
pulisher
Apr 30, 2026

NovoCure Limited (NVCR) Reports Strong Q1 2026 Results and FDA A - GuruFocus

Apr 30, 2026
pulisher
Apr 30, 2026

Novocure (NVCR) Shares Jump 22% on Strong Q1 Revenue and Raised Outlook - GuruFocus

Apr 30, 2026
pulisher
Apr 30, 2026

NovoCure (NASDAQ:NVCR) Shares Gap UpShould You Buy? - MarketBeat

Apr 30, 2026
pulisher
Apr 30, 2026

NovoCure: Q1 Earnings Snapshot - theheraldreview.com

Apr 30, 2026
pulisher
Apr 30, 2026

Novocure (NVCR) Reports Strong Q1 Revenue Growth - GuruFocus

Apr 30, 2026
pulisher
Apr 30, 2026

NVCR Stock Update: Insights on Current Market Trends - GuruFocus

Apr 30, 2026
pulisher
Apr 30, 2026

Novocure Jumps On Q1 Revenue Growth; Lifts FY26 Revenue Guidance - RTTNews

Apr 30, 2026
pulisher
Apr 30, 2026

NovoCure (NVCR) Q1: EPS -0.62 (miss vs -0.51 est.), Revenue $174 - GuruFocus

Apr 30, 2026
pulisher
Apr 30, 2026

NovoCure Reports Revenue Growth Driven by New Pancreatic Cancer Therapy - HarianBasis.co

Apr 30, 2026
pulisher
Apr 30, 2026

NovoCure Q1 Earnings Call Highlights - MarketBeat

Apr 30, 2026
pulisher
Apr 30, 2026

NovoCure Limited 2026 Q1ResultsEarnings Call Presentation (NASDAQ:NVCR) 2026-04-30 - Seeking Alpha

Apr 30, 2026
pulisher
Apr 30, 2026

NovoCure (NVCR) Reports Q1 Loss, Beats Revenue Estimates - Yahoo! Finance Canada

Apr 30, 2026
pulisher
Apr 30, 2026

NovoCure Ltd reports first quarter 2026 earnings performance - Traders Union

Apr 30, 2026
pulisher
Apr 30, 2026

Novocure reports Q1 2026 revenue $174.1M, adjusted EBITDA $(0.3)M, net loss $71.1M - TradingView

Apr 30, 2026
pulisher
Apr 30, 2026

Novocure (NASDAQ: NVCR) grows Q1 revenue and raises 2026 outlook - Stock Titan

Apr 30, 2026
pulisher
Apr 30, 2026

NovoCure (NASDAQ: NVCR) grows Q1 2026 revenue while investing in new cancer indications - Stock Titan

Apr 30, 2026
pulisher
Apr 30, 2026

New pancreatic cancer launch helps Novocure reach $174M in Q1 revenue - Stock Titan

Apr 30, 2026
pulisher
Apr 29, 2026

Novocure earnings in focus as new pancreatic therapy debuts By Investing.com - Investing.com Nigeria

Apr 29, 2026
pulisher
Apr 29, 2026

Novocure earnings in focus as new pancreatic therapy debuts - Investing.com UK

Apr 29, 2026
pulisher
Apr 28, 2026

NovoCure (NASDAQ: NVCR) director converts options into 21,500 shares - Stock Titan

Apr 28, 2026
pulisher
Apr 28, 2026

Vanguard (NVCR) holds 6.34M shares, 5.57% stake disclosed in 13G - Stock Titan

Apr 28, 2026
pulisher
Apr 25, 2026

NovoCure Limited (NASDAQ:NVCR) Given Consensus Rating of "Hold" by Analysts - MarketBeat

Apr 25, 2026
pulisher
Apr 24, 2026

Earnings Preview: Novocure to Report Financial Results Pre-market on April 30 - Moomoo

Apr 24, 2026
pulisher
Apr 24, 2026

CEO Frank Leonard's new NovoCure (NASDAQ: NVCR) contract outlines pay - Stock Titan

Apr 24, 2026
pulisher
Apr 23, 2026

NovoCure (NVCR) to Release Quarterly Earnings on Thursday - MarketBeat

Apr 23, 2026
pulisher
Apr 22, 2026

NovoCure Ltd (NVCR) Stock Up 6.5% and Still Undervalued -- GF Sc - GuruFocus

Apr 22, 2026
pulisher
Apr 21, 2026

NovoCure : Financial Reports 2026 novocure corporate responsibility report - marketscreener.com

Apr 21, 2026
pulisher
Apr 21, 2026

Total debt per share of NovoCure Ltd. – SWB:038 - TradingView

Apr 21, 2026
pulisher
Apr 20, 2026

NovoCure Ltd stock (JE00B6T5S470): Is tumor treating fields therapy strong enough to unlock new upsi - AD HOC NEWS

Apr 20, 2026
pulisher
Apr 20, 2026

[DEF 14A] NovoCure Ltd Definitive Proxy Statement - Stock Titan

Apr 20, 2026

Novocure Ltd Stock (NVCR) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
ZBH ZBH
$83.01
price up icon 0.41%
STE STE
$212.97
price up icon 0.34%
$59.48
price down icon 0.93%
PHG PHG
$26.45
price up icon 0.80%
$61.04
price up icon 0.07%
EW EW
$82.91
price down icon 0.50%
Cap:     |  Volume (24h):